How large is the proposed financing and how could it affect existing shareholders?

CoreWeave plans $3.0 billion of 2033 convertible notes plus an optional $500 million, and it may sell up to 35 million common shares under an ATM and forward structure. Conversions could dilute holders, but capped calls are intended to reduce that dilution up to a cap, and the company may settle conversions in cash or shares at its election.

What are the key terms of the convertible notes?

The notes mature April 1, 2033, are senior unsecured and guaranteed by certain subsidiaries, and bear cash interest semi-annually. The investor deck indicates a 2.375%–2.875% expected coupon and a 22.5%–27.5% conversion premium, but final terms are set at pricing. The notes are offered only to qualified institutional buyers under Rule 144A.

What will the company do with the proceeds?

A portion funds the capped call transactions and the remainder goes to general corporate purposes. Any proceeds from the equity program, including future collared forward settlements, are also earmarked for general corporate purposes such as debt repayment, capex, acquisitions, and supporting an investment-grade migration.

What does the business momentum look like behind the raise?

Q2 2026 revenue rose 112% year over year to $2.6 billion, and backlog reached $104.2 billion, up 246%. Management also cited more than $25 billion of new commitments in early Q3, but margins remain thin (5% adjusted operating margin) and GAAP net losses continue, so the financing is sizable relative to current profitability.

What are the main risks for investors to weigh?

Key risks include dilution from conversions and forward share sales, hedging activity by option counterparties that may move the stock price, heavy ongoing capex and leverage (about $38.6 billion of debt), persistent GAAP and adjusted net losses, and the risk that backlog conversion or contract execution underperforms. Investors should review the risk factors in the company's 10-Q and the offering memorandum.

CRWV 8-K: Regulation FD

01—Abstract

Summary

Summary of the 8-K filed September 17, 2026. Cited figures are marked; the original filing is the authoritative source.

CoreWeave (CRWV) announced on September 17, 2026 that it intends to sell $3.0 billion^a of convertible senior notes due April 1, 2033 in a Rule 144A private offering, with a $500 million greenshoe.

The notes will be senior unsecured obligations guaranteed by certain wholly owned subsidiaries, and conversions may be settled in cash, stock, or a combination at the company's election. Proceeds will partly fund capped call transactions, which are designed to reduce dilution, with the remainder going to general corporate purposes. Per the supplemental investor deck, the expected coupon is 2.375%^b–2.875% and the expected conversion premium is 22.5%–27.5%, with pricing expected after market close that day.

The same filing discloses an Equity Distribution Agreement allowing the company to sell up to 35,000,000 shares of Class A common stock through at-the-market sales, privately negotiated transactions, and collared forward sale agreements. Sales agent commissions are up to 2.0%^c, and no sales may occur until at least 30 days after the convertible purchase agreement. The company will receive no proceeds from forward-seller hedging until settlement, and the forward structure introduces future dilution and share-settlement mechanics that investors should model carefully.

Stated uses include general corporate purposes and support for migrating the enterprise credit profile toward investment grade. The deck supports the financing rationale with Q2 2026 results: revenue of $2.6 billion^d (up 112% YoY), revenue backlog of $104.2 billion (up 246% YoY), and more than $25 billion of additional net new commitments added in early Q3. Adjusted operating margin was 5%, adjusted net loss was $(567) million, and capex was $9.4 billion.

Total debt is about $38.6 billion, against weighted average interest of 7.8% (Q2-26 pro forma for the convertible). Investors should weigh strong backlog growth against heavy capital needs, persistent GAAP losses, and substantial leverage.

02—Key points

Key Highlights

$3.0 billion convertible senior notes due 2033 offered in a Rule 144A private placement, with a $500 million greenshoe option (13-day window)
Expected coupon of 2.375%–2.875% and conversion premium of 22.5%–27.5% per the investor deck; final terms set at pricing
Capped call transactions planned to mitigate dilution from conversions, funded partly from note proceeds
Up to 35,000,000 shares of Class A common stock may be sold via an Equity Distribution Agreement, including collared forward sale agreements, with up to 2.0% agent commissions
Q2 2026 revenue of $2.6 billion (+112% YoY) and revenue backlog of $104.2 billion (+246% YoY), excluding over $25 billion of net new commitments added in early Q3
Q2 2026 adjusted operating margin of 5% and adjusted net loss of $(567) million; capex of $9.4 billion in the quarter
Total debt of about $38.6 billion; the company cites a stated goal of migrating toward investment-grade credit and cost-of-debt reduction

03—Questions

Frequently Asked Questions

How large is the proposed financing and how could it affect existing shareholders?
CoreWeave plans $3.0 billion of 2033 convertible notes plus an optional $500 million, and it may sell up to 35 million common shares under an ATM and forward structure. Conversions could dilute holders, but capped calls are intended to reduce that dilution up to a cap, and the company may settle conversions in cash or shares at its election.
What are the key terms of the convertible notes?
The notes mature April 1, 2033, are senior unsecured and guaranteed by certain subsidiaries, and bear cash interest semi-annually. The investor deck indicates a 2.375%–2.875% expected coupon and a 22.5%–27.5% conversion premium, but final terms are set at pricing. The notes are offered only to qualified institutional buyers under Rule 144A.
What will the company do with the proceeds?
A portion funds the capped call transactions and the remainder goes to general corporate purposes. Any proceeds from the equity program, including future collared forward settlements, are also earmarked for general corporate purposes such as debt repayment, capex, acquisitions, and supporting an investment-grade migration.
What does the business momentum look like behind the raise?
Q2 2026 revenue rose 112% year over year to $2.6 billion, and backlog reached $104.2 billion, up 246%. Management also cited more than $25 billion of new commitments in early Q3, but margins remain thin (5% adjusted operating margin) and GAAP net losses continue, so the financing is sizable relative to current profitability.
What are the main risks for investors to weigh?
Key risks include dilution from conversions and forward share sales, hedging activity by option counterparties that may move the stock price, heavy ongoing capex and leverage (about $38.6 billion of debt), persistent GAAP and adjusted net losses, and the risk that backlog conversion or contract execution underperforms. Investors should review the risk factors in the company's 10-Q and the offering memorandum.

04—Continue

← View all 8-K filings